Inotuzumab Ozogamicin
A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory acute lymphoblastic leukemia (ITCC-059)
A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory acute lymphoblastic leukemia (ITCC-059)
Recruiting
Summary
This trial examines the safety and tolerability of inotuzumab. Patients with relapsed or refractory CD22 positive B-precursor leukemia (stratum A) or other CD22-positive B-cell cancers (stratum B) can be included in this trial.
Main inclusion criteria
- Age: > 1 and < 18 years
- CD22-positive ALL, relapsed or refractory BCP-ALL (Stratum A), relapsed or refractory CD22-positive B-cell malignancy including but not limited to diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), Burkitt lymphoma, Burkitt leukemia or B-cell precursor lymphoblastic lymphoma (Stratum B)
Sponsor
Erasmus Medical Center,
Niederlande